• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于在药物研发和监管中使用真实世界数据（RWD）和真实世界证据（RWE）的现状报告。

Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.

机构信息

Clinical Pharmacology, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

ARJUNA Therapeutics, C/ XESTA №78-A2, PARQUE EMPRESARIAL NOVO MILLADOIRO - 15895 MILLADOIRO, A CORUÑA, Spain.

出版信息

Br J Clin Pharmacol. 2019 Sep;85(9):1874-1877. doi: 10.1111/bcp.14026. Epub 2019 Jul 10.

DOI:10.1111/bcp.14026
PMID:31290181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6710497/
Abstract

Radically expanding use of real-world data (RWD) and real-world evidence (RWE) holds the potential to substantially impact drug development, pharmaceutical regulation, and payment within health care systems. Central to this is the reconfiguration of data gathering and transformation of data to information, which can be used as evidence for decision making. We discuss applications of this paradigm in the light of recent developments in both the United States and Europe on RWD and RWE.

摘要

真实世界数据（RWD）和真实世界证据（RWE）的广泛应用具有极大潜力，可能会对药物研发、药品监管和医疗保健系统内的支付方式产生重大影响。这一过程的核心是重新配置数据收集并将数据转化为信息，这些信息可用作决策证据。我们根据美国和欧洲最近在 RWD 和 RWE 方面的发展情况，讨论了这一模式的应用。

相似文献

1
Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.关于在药物研发和监管中使用真实世界数据（RWD）和真实世界证据（RWE）的现状报告。
Br J Clin Pharmacol. 2019 Sep;85(9):1874-1877. doi: 10.1111/bcp.14026. Epub 2019 Jul 10.
2
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.2018-2019 年在欧洲集中授权药物的药品开发中使用真实世界数据和证据。
Clin Pharmacol Ther. 2022 Jan;111(1):310-320. doi: 10.1002/cpt.2462. Epub 2021 Nov 16.
3
Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.利用真实世界证据支持美国罕见病监管决策：现状与未来方向
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1213-1218. doi: 10.1002/pds.4962. Epub 2020 Jan 30.
4
The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.新 FDA 真实世界证据计划支持药物和生物制品的开发。
J Diabetes Sci Technol. 2020 Mar;14(2):345-349. doi: 10.1177/1932296819832661. Epub 2019 Mar 12.
5
Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.美国和欧盟医疗保健领域的真实世界数据与真实世界证据
Bioengineering (Basel). 2024 Aug 2;11(8):784. doi: 10.3390/bioengineering11080784.
6
Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval-An Industry Perspective.真实世界数据和真实世界证据在药物研发与审批中的临床药理学应用——行业视角
Clin Pharmacol Ther. 2023 Oct;114(4):751-767. doi: 10.1002/cpt.2988. Epub 2023 Jul 29.
7
Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.日本真实世界数据与真实世界证据的现状、挑战及未来展望
Drugs Real World Outcomes. 2021 Dec;8(4):459-480. doi: 10.1007/s40801-021-00266-3. Epub 2021 Jun 19.
8
Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.亚洲用于报销决策的卫生技术评估的真实世界数据：现状与未来方向。
Int J Technol Assess Health Care. 2020 Oct;36(5):474-480. doi: 10.1017/S0266462320000628. Epub 2020 Sep 15.
9
How can real-world evidence aid decision making during the life cycle of nonprescription medicines?真实世界证据如何在非处方药生命周期中辅助决策？
Clin Transl Sci. 2022 Jan;15(1):43-54. doi: 10.1111/cts.13129. Epub 2021 Nov 15.
10
Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation.真实世界数据对市场准入、报销决策和价格谈判的影响。
Ther Innov Regul Sci. 2021 Jan;55(1):228-238. doi: 10.1007/s43441-020-00208-1. Epub 2020 Aug 28.

引用本文的文献

1
Navigating challenges and opportunities in orphan medicines: A spotlight commentary on rare diseases.应对孤儿药领域的挑战与机遇：关于罕见病的聚焦评论
Br J Clin Pharmacol. 2025 Apr;91(4):1084-1087. doi: 10.1002/bcp.70013. Epub 2025 Feb 16.
2
Expanding the use of real-world data through the development of user-friendly tools to support drug development: Example of an organ impairment dashboard.通过开发用户友好型工具来支持药物研发，从而扩大真实世界数据的应用：器官损伤仪表盘示例。
Pharmacol Res Perspect. 2024 Aug;12(4):e1239. doi: 10.1002/prp2.1239.
3
Psychostimulants and social behaviors.精神兴奋剂与社会行为。
Front Pharmacol. 2024 Apr 25;15:1364630. doi: 10.3389/fphar.2024.1364630. eCollection 2024.
4
Next-generation study databases require FAIR, EHR-integrated, and scalable Electronic Data Capture for medical documentation and decision support.下一代研究数据库需要具备FAIR原则、电子健康记录集成且可扩展的电子数据采集功能，以用于医疗文档记录和决策支持。
NPJ Digit Med. 2024 Jan 12;7(1):10. doi: 10.1038/s41746-023-00994-6.
5
Innovative thinking of clinical investigation for rare disease drug development.罕见病药物研发的临床研究创新思路。
Orphanet J Rare Dis. 2023 Sep 22;18(1):299. doi: 10.1186/s13023-023-02909-w.
6
A Road Map for Peer Review of Real-World Evidence Studies on Safety and Effectiveness of Treatments.真实世界证据研究中治疗安全性和有效性的同行评议路线图
Diabetes Care. 2023 Aug 1;46(8):1448-1454. doi: 10.2337/dc22-2037.
7
Evaluation of reporting quality of cohort studies using real-world data based on RECORD: systematic review.基于 RECORD 评价真实世界数据队列研究报告质量：系统评价。
BMC Med Res Methodol. 2023 Jun 29;23(1):152. doi: 10.1186/s12874-023-01960-2.
8
Harnessing Real-World Evidence to Advance Cancer Research.利用真实世界证据推进癌症研究。
Curr Oncol. 2023 Feb 2;30(2):1844-1859. doi: 10.3390/curroncol30020143.
9
Real-world use of orphan medicinal products (OMPs) in rare disease (RD) patients: A population-based registry study.罕见病（RD）患者中孤儿药（OMPs）的真实世界使用情况：一项基于人群的注册研究。
Front Pharmacol. 2022 Sep 30;13:940010. doi: 10.3389/fphar.2022.940010. eCollection 2022.
10
RWD-Cockpit: Application for Quality Assessment of Real-world Data.真实世界数据驾驶舱：真实世界数据质量评估应用程序。
JMIR Form Res. 2022 Oct 18;6(10):e29920. doi: 10.2196/29920.

本文引用的文献

1
Use of FDA's Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure.使用 FDA 的 Sentinel 系统量化新雷诺嗪暴露后立即发生癫痫发作的风险。
Drug Saf. 2019 Jul;42(7):897-906. doi: 10.1007/s40264-019-00798-2.
2
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?数据丰富，信息匮乏：我们能否利用电子健康记录为制药行业创建学习型医疗保健系统？
Clin Pharmacol Ther. 2019 Apr;105(4):912-922. doi: 10.1002/cpt.1226. Epub 2018 Oct 14.
3
Accelerated approval of medicines: fit for purpose?药品加速审批：是否合适？
Nat Rev Drug Discov. 2018 Jun;17(6):379-380. doi: 10.1038/nrd.2017.245. Epub 2018 Jan 5.
4
When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?真实世界数据分析何时以及如何能够替代随机对照试验？
Clin Pharmacol Ther. 2017 Dec;102(6):924-933. doi: 10.1002/cpt.857. Epub 2017 Sep 25.
5
Improving therapeutic effectiveness and safety through big healthcare data.通过大型医疗数据提高治疗效果和安全性。
Clin Pharmacol Ther. 2016 Mar;99(3):262-5. doi: 10.1002/cpt.316. Epub 2016 Jan 17.
6
Obtaining real-world evidence: the Salford Lung Study.获取真实世界证据：索尔福德肺部研究。
Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6.
7
Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.使用抗糖尿病药物与胰腺癌风险：病例对照分析。
Am J Gastroenterol. 2012 Apr;107(4):620-6. doi: 10.1038/ajg.2011.483. Epub 2012 Jan 31.
8
Dopamine agonist use and the risk of heart failure.多巴胺激动剂的使用与心力衰竭风险。
Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):34-41. doi: 10.1002/pds.2267. Epub 2011 Nov 23.
9
Reemergence of PML in natalizumab-treated patients--new cases, same concerns.那他珠单抗治疗患者中进行性多灶性白质脑病的再次出现——新病例，同样的担忧。
N Engl J Med. 2009 Sep 10;361(11):1041-3. doi: 10.1056/NEJMp0906248.
10
The British Society for Rheumatology biologics register.英国风湿病学会生物制剂登记册。
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv42-3. doi: 10.1136/ard.2005.042499.